Dyne Therapeutics

DYN58

High Growth

$29.69arrow_drop_down0.20%-$0.05

High Growth

DYN58

$29.69

arrow_drop_down0.20%-$0.05

High Growth

Performance History

Key Stats
Open	$29.47
Prev. Close	$29.68
EPS	-3.58
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	28.51	30.30
52 Week Range	6.40	47.45

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.58

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Dyne Therapeutics (DYN)

Dyne Therapeutics Inc (DYN) is a biotechnology company that focuses on developing innovative therapies for patients with serious muscle diseases. The company is dedicated to advancing the field of muscle biology and has created a unique approach to treating muscle disorders. Their primary focus is on developing therapies for patients with rare genetic muscle diseases, such as myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD).

Dyne Therapeutics Inc was founded in 2019 and has quickly gained recognition for its groundbreaking research and development efforts. The company's innovative platform utilizes oligonucleotides to selectively target muscle cells and deliver therapeutic molecules directly to the affected tissues. This approach has the potential to revolutionize the treatment of muscle diseases by addressing the underlying genetic causes.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Joshua T. Brumm
Headquarters: Waltham
Employees: 134
Exchange: NASDAQ

Keep an eye on Dyne Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Dyne Therapeutics 's (DYN) price per share?

The current price per share for Dyne Therapeutics (DYN) is $29.69. The stock has seen a price change of -$0.06 recently, indicating a -0.2% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Dyne Therapeutics (DYN)?

For Dyne Therapeutics (DYN), the 52-week high is $47.45, which is 59.82% from the current price. The 52-week low is $6.4, the current price is 363.91% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Dyne Therapeutics (DYN) a growth stock?

Dyne Therapeutics (DYN) has shown an average price growth of -6.03% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Dyne Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Dyne Therapeutics (DYN) stock price performance year to date (YTD)?

As of the latest data, Dyne Therapeutics (DYN) has a year-to-date price change of 127.34%. Over the past month, the stock has experienced a price change of -11.32%. Over the last three months, the change has been -36.88%. Over the past six months, the figure is -9.01%.

help

Is Dyne Therapeutics (DYN) a profitable company?

Dyne Therapeutics (DYN) has a net income of -$235.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$242.16M. Furthermore, the EBITDA is -$312.84M.

help

What is the market capitalization of Dyne Therapeutics (DYN)?

Dyne Therapeutics (DYN) has a market capitalization of $3.02B. The average daily trading volume is 29.86, indicating the stock's liquidity and investor engagement.

News

HEALTH

CLINICAL STUDY

Jun 24, 2024

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

CLINICAL STUDY

Jun 13, 2024

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

MACRO ECONOMIC EVENTS

MACRO NOTIFICATION

BROAD U.S. EQUITY ETFS

SMALL CAP

ECON #S